Reneo Pharmaceuticals Inc (RPHM) USD0.0001
$0.005
(0.33%)
- Add to watchlist
- This stock can be held in a
$0.005
(0.33%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.005
(0.33%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Reneo Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Contact details
Important dates
General stock information
- Short code:
- RPHM
- ISIN:
- US75974E1038
- Market cap:
- $46.47 million
- Shares in issue:
- 33.43 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.